Harrow Inc
HROW34.930USD
+3.560+11.35%
收盘 07/11, 16:00（美东）报价延迟15分钟
1.25B总市值
亏损市盈率 TTM
关于 Harrow Inc 公司
Harrow, Inc. 是一家眼科药品公司。该公司致力于为美国市场发现、开发和销售眼科药品。它提供全面的处方药和非处方药产品组合。它拥有北美品牌眼科药品组合的商业权利，所有这些产品均以 Harrow 的名义销售。它拥有并经营 ImprimisRx，这是一家专注于眼科的药物配制企业。它拥有各种产品的美国商业权利：IHEEZO、VEVYE、TRIESENCE、VIGAMOX、ILEVRO、FLAREX、NATACYN、ZERVIATE 等。VIGAMOX（盐酸莫西沙星滴眼液）0.5%，是一种氟喹诺酮类抗生素滴眼液，用于治疗由敏感菌株引起的细菌性结膜炎。 IHEEZO（盐酸氯普鲁卡因眼用凝胶）3%是一种用于眼表麻醉的低粘度凝胶。
公司简介
公司代码HROW
公司名称Harrow Inc
上市日期Feb 08, 2013
成立日期2006
CEOMr. John P. Saharek
员工数量382
证券类型Ordinary Share
年结日Feb 08
公司地址1A Burton Hills Blvd
城市NASHVILLE
上市交易所NASDAQ Global Market Consolidated
国家United States of America
邮编37215
电话16157334731
网址https://www.harrow.com/
公司代码HROW
上市日期Feb 08, 2013
成立日期2006
公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
Mr. Amir Shojaei, Ph.D.
Mr. Amir Shojaei, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Mark L. Baum, J.D.
Mr. Mark L. Baum, J.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
2.60M
+21.61%
Mr. Andrew R. Boll
Mr. Andrew R. Boll
Chief Financial Officer, Corporate Secretary
Chief Financial Officer, Corporate Secretary
777.84K
+36.92%
Mr. John P. Saharek
Mr. John P. Saharek
President and Chief Executive Officer of ImprimisRx
President and Chief Executive Officer of ImprimisRx
467.39K
+58.62%
Dr. Adrienne L. Graves, Ph.D.
Dr. Adrienne L. Graves, Ph.D.
Independent Director
Independent Director
--
--
Mrs. Lauren P. Silvernail
Mrs. Lauren P. Silvernail
Independent Director
Independent Director
--
--
Mr. Perry J. Sternberg
Mr. Perry J. Sternberg
Lead Independent Director
Lead Independent Director
--
--
收入明细
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
暂无数据
业务
地区
业务USD
名称
营收
占比
Product Sales Net
47.74M
0.00%
Transfer of acquired product sales/profit
86.00K
0.00%
股东统计
更新时间: 5月16日 周五
更新时间: 5月16日 周五
持股股东
股东类型
持股股东
持股股东
占比
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
持股股东
持股股东
占比
Opaleye Management Inc.
10.72%
Baum (Mark L)
7.08%
BlackRock Institutional Trust Company, N.A.
6.20%
Private Capital Management
5.15%
The Vanguard Group, Inc.
5.07%
Other
65.78%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
23.15%
Hedge Fund
18.11%
Individual Investor
15.07%
Investment Advisor
12.93%
Research Firm
2.04%
Pension Fund
0.45%
Bank and Trust
0.33%
Sovereign Wealth Fund
0.07%
Insurance Company
0.03%
Other
27.83%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
340
26.58M
72.44%
-3.00M
2025Q1
354
25.78M
70.87%
-4.22M
2024Q4
350
26.13M
73.38%
-4.49M
2024Q3
325
25.90M
72.95%
-2.80M
2024Q2
296
24.70M
70.19%
-6.36M
2024Q1
284
26.34M
74.95%
-7.20M
2023Q4
279
28.26M
80.94%
-4.94M
2023Q3
275
28.51M
81.73%
-152.59K
2023Q2
265
25.64M
85.30%
+312.85K
2023Q1
246
23.86M
79.81%
+1.57M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
Opaleye Management Inc.
3.94M
10.72%
-4.80K
-0.12%
Jun 04, 2025
Baum (Mark L)
2.60M
7.08%
+461.94K
+21.61%
Apr 21, 2025
BlackRock Institutional Trust Company, N.A.
2.27M
6.2%
-1.07K
-0.05%
Mar 31, 2025
Private Capital Management
1.89M
5.15%
+195.64K
+11.54%
Mar 31, 2025
The Vanguard Group, Inc.
1.86M
5.07%
-6.65K
-0.36%
Mar 31, 2025
Kaufman (Daniel)
1.68M
4.59%
-222.91K
-11.69%
Aug 12, 2024
Braidwell LP
956.84K
2.61%
+49.80K
+5.49%
Mar 31, 2025
State Street Global Advisors (US)
786.48K
2.14%
-41.22K
-4.98%
Mar 31, 2025
Boll (Andrew R)
777.84K
2.12%
+209.75K
+36.92%
Apr 21, 2025
Geode Capital Management, L.L.C.
774.08K
2.11%
+52.97K
+7.35%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
SPDR S&P Pharmaceuticals ETF
1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
0.76%
iShares U.S. Pharmaceuticals ETF
0.48%
First Trust Small Cap Growth AlphaDEX Fund
0.4%
iShares Micro-Cap ETF
0.19%
ProShares Ultra Nasdaq Biotechnology
0.13%
Invesco Nasdaq Biotechnology ETF
0.11%
Vanguard US Momentum Factor ETF
0.1%
Fidelity Small-Mid Multifactor ETF
0.09%
First Trust Multicap Growth Alphadex Fund
0.07%
查看更多
SPDR S&P Pharmaceuticals ETF
占比1.96%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
占比0.76%
iShares U.S. Pharmaceuticals ETF
占比0.48%
First Trust Small Cap Growth AlphaDEX Fund
占比0.4%
iShares Micro-Cap ETF
占比0.19%
ProShares Ultra Nasdaq Biotechnology
占比0.13%
Invesco Nasdaq Biotechnology ETF
占比0.11%
Vanguard US Momentum Factor ETF
占比0.1%
Fidelity Small-Mid Multifactor ETF
占比0.09%
First Trust Multicap Growth Alphadex Fund
占比0.07%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
